Get the Stockscreener App
10.52
2.14%
-0.23
After Hours:
10.52
Immunome Inc stock is traded at $10.52, with a volume of 560.48K.
It is down -2.14% in the last 24 hours and up +13.12% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$10.75
Open:
$10.67
24h Volume:
560.48K
Relative Volume:
0.58
Market Cap:
$915.37M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-3.1766
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-6.41%
1M Performance:
+13.12%
6M Performance:
-4.62%
1Y Performance:
-31.73%
1-Day Range:
$10.40
$10.78
1-Week Range:
$10.33
$11.29
52-Week Range:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.52 | 935.38M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Will Immunome Inc. continue its uptrendFree Profit Target Stock Opportunity Monitor - Newser
Why Immunome Inc. stock attracts strong analyst attentionLow Risk Strategy with Smart Entry Zones - Newser
New Product Launches: Will They Boost Immunome Inc. Stock in 2025Secure Entry Point Finder with Analysis - Newser
Risk vs reward if holding onto Immunome Inc.Technical Long-Term Outlook and Recap Guide - Newser
How Resilient Is Immunome Inc. Stock During Economic DownturnsFree Sector Based Breakout Stock Forecast - Newser
What’s next for Immunome Inc. stock priceCapital Growth Plan for New Investors - Newser
Strategies to average down on Immunome Inc.Weekly Trend Watch with Market Signals - Newser
Momentum Screeners Rank Immunome Inc. in Top 5 TodayWeekly Watchlist of High Movers Released - metal.it
What makes Immunome Inc. stock attractive to long term investorsPredictable Entry Strategy With Technical Backing - Newser
Sectors Driving Future Growth for Immunome Inc. StockSafe Entry Strategy with High Win Rate - Newser
How Immunome Inc. stock performs during market volatilityStable Profit Zone and Loss Control Analysis - Newser
What makes Immunome Inc. stock price move sharplyFree AI Screening for Swing Trade Picks - Newser
Will Immunome Inc. stock benefit from AI tech trendsPattern Breakout Prediction for Short Term - Newser
What are Immunome Inc. company’s key revenue driversBuild your wealth with consistent stock growth - jammulinksnews.com
Will Immunome Inc. continue its uptrend Free Technical Stock Breakout Predictions - Newser
What’s next for Immunome Inc. stock price Free Growth Focused Entry Plan Suggestions - Newser
How does Immunome Inc. compare to its industry peersCapitalize on market trends with expert guidance - jammulinksnews.com
What catalysts could drive Immunome Inc. stock higher in 2025Unlock powerful investment tools for free - jammulinksnews.com
What institutional investors are buying Immunome Inc. stockAchieve consistent high returns with low risk - jammulinksnews.com
When is Immunome Inc. stock expected to show significant growthAchieve rapid financial growth with expert help - jammulinksnews.com
Why is Immunome Inc. stock attracting strong analyst attentionInvest in stocks with long-term growth potential - jammulinksnews.com
Published on: 2025-07-28 03:29:08 - jammulinksnews.com
How strong is Immunome Inc. company’s balance sheetBreakout portfolio performance - jammulinksnews.com
Is Immunome Inc. Stock a Good Fit for Conservative InvestorsCarefully Curated High Return Stocks - metal.it
What analysts say about Immunome Inc. stockExplosive capital appreciation - PrintWeekIndia
Immunome Inc. Stock Analysis and ForecastFastest return on investment - PrintWeekIndia
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Arizona State Retirement System - Defense World
What drives Immunome Inc. stock priceUnprecedented profits - jammulinksnews.com
Is Immunome Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
Teacher Retirement System of Texas Boosts Stock Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):